About Candel

The cancer treatment paradigm has shifted dramatically over the last decade, providing evidence that the immune system can be reactivated against a patient’s tumor. However, most patients do not achieve stable disease remission with currently available immunotherapies.

At Candel Therapeutics, we are developing immunotherapies that induce immunogenic cell death in cancer cells at the site of injection, unmasking tumor neo-antigens within an activated microenvironment. This process leads to a systemic, durable immune response against the tumor, with the potential to change disease outcomes across a variety of indications.


Candel’s products are designed to significantly improve survival while maintaining quality of life – from early- to late-stage disease.

Our PURPOSE

to save, extend and improve the lives of patients through oncolytic viral immunotherapies.


Our PLAN

to harness the power of our proprietary virus-based approaches and elicit a broad, potent immune response against solid tumors and their metastases.

OUR LEADERSHIP

is made up of renowned drug developers, oncolytic viral immunotherapy experts, oncologists, immunologists and biotech business leaders. Candel is built on excellent science, and our experienced team is helping translate its full promise to patients.

RESEARCH ADVISORY BOARD

SCIENTIFIC ADVISORS

© 2021 by Candel Therapeutics